Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Murlidhar Rajagopalan"'
Autor:
Alison M. Layton, MB ChB, Andrew Alexis, MD, MPH, Hilary Baldwin, MD, Vincenzo Bettoli, MD, James Del Rosso, DO, Thomas Dirschka, MD, Brigitte Dréno, MD, PhD, Linda Stein Gold, MD, Julie Harper, MD, Joo Yeon Ko, MD, PhD, Khaled Al Nuaimi, MD, Hazel H. Oon, MD, Murlidhar Rajagopalan, MD, MBBS, Marco Rocha, MD, PhD, Jo-Ann See, MBBS, Jonathan Weiss, MD, Jerry Tan, MD
Publikováno v:
JAAD International, Vol 12, Iss , Pp 60-69 (2023)
Background: Acne, a commonly treated skin disease, requires patient-centered management due to its varying presentations, chronicity, and impact on health-related quality of life. Despite this, evidence-based clinical guidelines focus primarily on cl
Externí odkaz:
https://doaj.org/article/11bd54c939e14b30b7b834f62a207422
Autor:
Valencia Long, Ellie Ci-En Choi, Zhaojin Chen, Moonyza Akmal Ahmad Kamil, Murlidhar Rajagopalan, Erin McMeniman, Nisha Suyien Chandran
Publikováno v:
JMIR Dermatology, Vol 6, p e43910 (2023)
BackgroundThe field of teledermatology has expanded tremendously and has been used for conditions including hidradenitis suppurativa (HS). However, due to the sensitive location of lesions, HS may be considered less suitable for teledermatology. Obj
Externí odkaz:
https://doaj.org/article/b10474ac31474720b6a5adbfcb1fb58b
Autor:
Arnon D. Cohen, MD, MPH, PhD, Ronald Vender, MD, FRCPC, Luigi Naldi, MD, Robert E. Kalb, MD, Tiago Torres, MD, PhD, Murlidhar Rajagopalan, MD, Joelle van der Walt, PhD, Lluís Puig, MD (Hon), PhD, Helen S. Young, MB ChB, PhD, FRCP
Publikováno v:
JAAD International, Vol 1, Iss 2, Pp 224-230 (2020)
Background: As biosimilars have become available in various parts of the world, the International Psoriasis Council has reviewed aspects of their use. Objective: To provide consensus statements from the Biosimilar Working Group about the use of biosi
Externí odkaz:
https://doaj.org/article/0b6f4a54dbc947d2a36e56b94f2b29b1
Autor:
Murlidhar Rajagopalan, Abhishek De, Kiran Godse, D S Krupa Shankar, Vijay Zawar, Nidhi Sharma, Samipa Mukherjee, Aarti Sarda, Sandipan Dhar
Publikováno v:
Indian Journal of Dermatology, Vol 64, Iss 3, Pp 166-181 (2019)
Background: Atopic dermatitis (AD) is a common and chronic, pruritic inflammatory skin condition that affects all age groups. There was a dearth of consensus document on AD for Indian practitioners. This article aims to provide an evidence-based cons
Externí odkaz:
https://doaj.org/article/de0265bf90cb4ffba6f68ad7e6c9008a
Publikováno v:
Indian Journal of Dermatology, Vol 63, Iss 1, Pp 30-40 (2018)
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is also known as drug induced hypersensitivity syndrome and by various other names. It is now recognised as one of the severe cutaneous adverse reaction (SCAR) and can be potenti
Externí odkaz:
https://doaj.org/article/c58c2ef9ab474ebc9006edf836f31feb
Autor:
Kiran Godse, Abhishek De, Vijay Zawar, Bela Shah, Mukesh Girdhar, Murlidhar Rajagopalan, D S Krupashankar
Publikováno v:
Indian Journal of Dermatology, Vol 63, Iss 1, Pp 2-15 (2018)
This article is developed by the Skin Allergy Research Society of India for an updated evidence-based consensus statement for the management of urticaria, with a special reference to the Indian context. This guideline includes updated definition, cau
Externí odkaz:
https://doaj.org/article/e989960a7ec340569dfd36925cd95ff9
Autor:
Murlidhar Rajagopalan, Abir Saraswat, Kiran Godse, D S Krupa Shankar, Sanjiv Kandhari, Shrutakirthi D Shenoi, Sushil Tahiliani, V Vijay Zawar
Publikováno v:
Indian Journal of Dermatology, Vol 62, Iss 1, Pp 7-17 (2017)
The aim of this study is to formulate the best clinical practice in the diagnosis and management of chronic pruritus (CP). We searched PubMed, EMBASE, Scopus, Web of Science, and the WHO's regional databases, for studies on “Diagnosis and managemen
Externí odkaz:
https://doaj.org/article/748ddde45ab24f28820588414c276b1c
Autor:
Murlidhar Rajagopalan, Asit Mital
Publikováno v:
Indian Dermatology Online Journal, Vol 7, Iss 6, Pp 489-497 (2016)
The biologics currently in use for psoriasis in India are etanercept, infliximab and recently introduced itolizumab and secukinumab. Biosimilars, expected to play a significant role in psoriasis management in future, have also been available for the
Externí odkaz:
https://doaj.org/article/bcc71839221845f3b8e172567e21c64b
Autor:
Kiran Godse, Murlidhar Rajagopalan, Mukesh Girdhar, Sanjiv Kandhari, Bela Shah, Prashant N Chhajed, Sushil Tahiliani, D S Krupa Shankar, Vijay Somani, Vijay Zawar
Publikováno v:
Indian Dermatology Online Journal, Vol 7, Iss 1, Pp 6-11 (2016)
Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H1-antihistamines. Omalizumab is a humanized monoclonal anti-IgE antibody that binds with free IgE anti
Externí odkaz:
https://doaj.org/article/11a21d0048f045c5ad97aa3557538c75
Publikováno v:
Indian Journal of Dermatology, Vol 62, Iss 5, Pp 533-535 (2017)
Externí odkaz:
https://doaj.org/article/23167031283b4683bc1257bd87336364